Forgot password?
   Please leave this field empty
COVID-19 MSAB Home page banner
Questions and Answers Regarding COVID-19 Vaccines from the Medical & Scientific Advisory Board

Read the Statement >>

Scleroderma Foundation More than Doubles Research Commitment

Important Updates on COVID Masks for People with Scleroderma


What is Scleroderma?

Scleroderma is a rare disease that affects connective tissue and the vascular system. Generally classified as an autoimmune rheumatic disease, an overproduction of collagen (fibrosis) hardens tissue and damages organs. Commonly affecting the skin (called localized), scleroderma also affects internal organs (systemic sclerosis) and can be life-threatening. Anyone can have scleroderma. No one knows what causes the disease, although there are many clues including genetic predisposition. There is no cure and no drugs that halt the progression of the disease or reverse it. The fibrosis at the center of scleroderma makes it prototypic for all other fibrotic diseases.

Who We Are

The Scleroderma Foundation’s threefold mission provides emotional support and disease education while funding innovative research to discover the cause, understand the mechanisms and overcome scleroderma forever. With historical roots from the 1970s and a nation-wide network of chapters, the Foundation’s signature National Scleroderma Conference provides access to expert information and is the centerpiece of the community. The Foundation’s Medical & Scientific Advisory Board is comprised of world-renowned scleroderma experts who guide the organization’s health-related policies. Its Peer-Review Research Program emphasizes scientific merit, and its novel Patients as Partners program promotes collaboration between pharmaceutical and biotech entities and people living with scleroderma in the design of clinical trials.

Read more >>

Download Our Free Scleroderma Information Packet

Can’t download It? Have us mail you a copy!

Buzzworthy Reads>>

scleroderma body thumbnail vertical.jpg

See our GuideStar profile

eLetter

Visit the eLetter Archive to read the stories behind these headlines.Submit your email address to receive the eLetter every week.

eLetter #935: September 17, 2021

  • COVID-19 Vaccine Response in Autoimmune Diseases
  • COVID-19 Update; VIDEO: July 2021, National Scleroderma Conference
  • The 20%: A Virtual Support Group for Males Living with Scleroderma. TOPIC: Intimacy and Scleroderma; ZOOM: Wed., Sept. 22; 7 to 8 p.m. Eastern Time
  • Rocky Mountain Scleroderma Education Summit; ZOOM: Sat., Sept. 25; 10 a.m. to 1:45 p.m. Mountain Time
  • Research Study to Evaluate an Online Fatigue Intervention Program
  • Permission Cards
  • Rheumatic Disease Awareness Month
  • Pulmonary Fibrosis Awareness Month
  • Proud Partner with World Lung Day
  • Kids Get Scleroderma, Too! Save the Date; VIRTUAL: October 23, 2021
  • 9th PeDRA Annual Conference; VIRTUAL: October 14-15, 2021
  • Ticket to Work: Support on Your Journey to Employment; VIRTUAL: Wed., Sept. 22, 2021, 3-4:30 p.m. Eastern Time
  • Quiz: Can You Differentiate Pulmonary Hypertension From Hypertension?
 

E-Newsletter Signup

Get the latest news.

Please leave this field empty

Our Sponsors